HRP20191559T1 - Farmaceutski pripravci za liječenje infekcije bakterijom helicobacter pylori - Google Patents
Farmaceutski pripravci za liječenje infekcije bakterijom helicobacter pylori Download PDFInfo
- Publication number
- HRP20191559T1 HRP20191559T1 HRP20191559T HRP20191559T1 HR P20191559 T1 HRP20191559 T1 HR P20191559T1 HR P20191559 T HRP20191559 T HR P20191559T HR P20191559 T1 HRP20191559 T1 HR P20191559T1
- Authority
- HR
- Croatia
- Prior art keywords
- capsule according
- dose
- preparation
- release
- amoxicillin
- Prior art date
Links
- 241000590002 Helicobacter pylori Species 0.000 title 1
- 229940037467 helicobacter pylori Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000002775 capsule Substances 0.000 claims 24
- 238000002360 preparation method Methods 0.000 claims 10
- 229960000885 rifabutin Drugs 0.000 claims 8
- 229960003022 amoxicillin Drugs 0.000 claims 7
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 claims 7
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 claims 7
- ZWBTYMGEBZUQTK-PVLSIAFMSA-N [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,32-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-1'-(2-methylpropyl)-6,23-dioxospiro[8,33-dioxa-24,27,29-triazapentacyclo[23.6.1.14,7.05,31.026,30]tritriaconta-1(32),2,4,9,19,21,24,26,30-nonaene-28,4'-piperidine]-13-yl] acetate Chemical compound CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c4NC5(CCN(CC(C)C)CC5)N=c4c(=NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C ZWBTYMGEBZUQTK-PVLSIAFMSA-N 0.000 claims 6
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims 5
- 229960000381 omeprazole Drugs 0.000 claims 5
- 229940126409 proton pump inhibitor Drugs 0.000 claims 5
- 239000000612 proton pump inhibitor Substances 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 239000012453 solvate Substances 0.000 claims 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims 4
- 239000001913 cellulose Substances 0.000 claims 3
- 229920002678 cellulose Polymers 0.000 claims 3
- 235000010980 cellulose Nutrition 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000011248 coating agent Substances 0.000 claims 3
- 238000000576 coating method Methods 0.000 claims 3
- 230000001934 delay Effects 0.000 claims 3
- 238000009472 formulation Methods 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 claims 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims 2
- 229920002472 Starch Polymers 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 230000003113 alkalizing effect Effects 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 229940088710 antibiotic agent Drugs 0.000 claims 2
- 239000011230 binding agent Substances 0.000 claims 2
- 229910000019 calcium carbonate Inorganic materials 0.000 claims 2
- 235000010216 calcium carbonate Nutrition 0.000 claims 2
- 230000003111 delayed effect Effects 0.000 claims 2
- 239000000945 filler Substances 0.000 claims 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 2
- 239000000314 lubricant Substances 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 239000008185 minitablet Substances 0.000 claims 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 239000011241 protective layer Substances 0.000 claims 2
- ATEBXHFBFRCZMA-VXTBVIBXSA-N rifabutin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC(=C2N3)C(=O)C=4C(O)=C5C)C)OC)C5=C1C=4C2=NC13CCN(CC(C)C)CC1 ATEBXHFBFRCZMA-VXTBVIBXSA-N 0.000 claims 2
- 239000008107 starch Substances 0.000 claims 2
- 235000019698 starch Nutrition 0.000 claims 2
- 229940032147 starch Drugs 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- 229920002554 vinyl polymer Polymers 0.000 claims 2
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims 1
- 229920001817 Agar Polymers 0.000 claims 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 1
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 1
- SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims 1
- IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 claims 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 1
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- -1 acetate--polyethylene Chemical group 0.000 claims 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
- 150000001253 acrylic acids Chemical class 0.000 claims 1
- 239000008272 agar Substances 0.000 claims 1
- 229940023476 agar Drugs 0.000 claims 1
- 235000010419 agar Nutrition 0.000 claims 1
- 235000010443 alginic acid Nutrition 0.000 claims 1
- 239000000783 alginic acid Substances 0.000 claims 1
- 229920000615 alginic acid Polymers 0.000 claims 1
- 229960001126 alginic acid Drugs 0.000 claims 1
- 150000004781 alginic acids Chemical class 0.000 claims 1
- 239000001506 calcium phosphate Substances 0.000 claims 1
- 235000011010 calcium phosphates Nutrition 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 1
- 229940105329 carboxymethylcellulose Drugs 0.000 claims 1
- 229960001681 croscarmellose sodium Drugs 0.000 claims 1
- 229960000913 crospovidone Drugs 0.000 claims 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 1
- 229960003568 dexlansoprazole Drugs 0.000 claims 1
- MJIHNNLFOKEZEW-RUZDIDTESA-N dexlansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-RUZDIDTESA-N 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 239000002702 enteric coating Substances 0.000 claims 1
- 238000009505 enteric coating Methods 0.000 claims 1
- 229960004770 esomeprazole Drugs 0.000 claims 1
- SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical compound C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 claims 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims 1
- 229940049654 glyceryl behenate Drugs 0.000 claims 1
- 229940074045 glyceryl distearate Drugs 0.000 claims 1
- 229940075507 glyceryl monostearate Drugs 0.000 claims 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 1
- 229940072106 hydroxystearate Drugs 0.000 claims 1
- HRRXCXABAPSOCP-UHFFFAOYSA-N ilaprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC(=CC=C3N=2)N2C=CC=C2)=C1C HRRXCXABAPSOCP-UHFFFAOYSA-N 0.000 claims 1
- 229950008491 ilaprazole Drugs 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 229960003174 lansoprazole Drugs 0.000 claims 1
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 229960003194 meglumine Drugs 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
- 229960005019 pantoprazole Drugs 0.000 claims 1
- 239000008363 phosphate buffer Substances 0.000 claims 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims 1
- 229920001451 polypropylene glycol Polymers 0.000 claims 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 229960004157 rabeprazole Drugs 0.000 claims 1
- YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 claims 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims 1
- 229960001225 rifampicin Drugs 0.000 claims 1
- 239000000377 silicon dioxide Substances 0.000 claims 1
- 235000012239 silicon dioxide Nutrition 0.000 claims 1
- 235000010413 sodium alginate Nutrition 0.000 claims 1
- 239000000661 sodium alginate Substances 0.000 claims 1
- 229940005550 sodium alginate Drugs 0.000 claims 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims 1
- 235000017557 sodium bicarbonate Nutrition 0.000 claims 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 1
- 239000008109 sodium starch glycolate Substances 0.000 claims 1
- 229940079832 sodium starch glycolate Drugs 0.000 claims 1
- 229920003109 sodium starch glycolate Polymers 0.000 claims 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims 1
- 229910052938 sodium sulfate Inorganic materials 0.000 claims 1
- 235000011152 sodium sulphate Nutrition 0.000 claims 1
- 239000008117 stearic acid Substances 0.000 claims 1
- 235000000346 sugar Nutrition 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 239000000454 talc Substances 0.000 claims 1
- 229910052623 talc Inorganic materials 0.000 claims 1
- 235000012222 talc Nutrition 0.000 claims 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims 1
- 239000000230 xanthan gum Substances 0.000 claims 1
- 235000010493 xanthan gum Nutrition 0.000 claims 1
- 229920001285 xanthan gum Polymers 0.000 claims 1
- 229940082509 xanthan gum Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4747—Quinolines; Isoquinolines spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Claims (23)
1. Kapsula koja sadrži:
(1) pripravak prve doze s trenutnim otpuštanjem u obliku komprimiranih minitableta, pripravak prve doze s trenutnim otpuštanjem koji se sastoji od najmanje dva antibiotika te
(2) pripravak druge doze s odgođenim otpuštanjem u obliku komprimiranih minitableta, pripravak druge doze s odgođenim otpuštanjem koji se sastoji od inhibitora protonske pumpe i obloge,
naznačen time što je, kada se testira u uređaju s košaricom, obloga pripravka druge doze s odgođenim otpuštanjem osmišljena tako da ispunjava kriterije profila otapanja u dvofaznom testu u uređaju s košaricom:
(a) otpuštanje najviše 10 % prema težini inhibitora protonske pumpe tijekom 120 minuta u kiseloj fazi s 900 ml 0,1 N HCl pri 100 o/min te
(b) otpuštanje najmanje 75 % prema težini inhibitora protonske pumpe tijekom 45 minuta u 900 ml fosfatnog pufera pH vrijednosti 6,8 pri 100 o/min nakon primjene kiseline.
2. Kapsula u skladu s patentnim zahtjevom 1, naznačena time što obloga u pripravku druge doze odgađa otpuštanje inhibitora protonske pumpe sa 120 na najmanje 240 minuta nakon peroralne primjene.
3. Kapsula u skladu s patentnim zahtjevom 1, naznačena time što pripravak prve doze sadrži amoksicilin i ansamicin ili farmaceutski prihvatljive soli ili njihove solvate.
4. Kapsula u skladu s patentnim zahtjevom 3, naznačena time što ansamicin sadrži rifampicin, rifabutin, farmaceutski prihvatljive soli ili njihove solvate ili kombinacije navedenog.
5. Kapsula u skladu s patentnim zahtjevom 1, naznačena time što u pripravku druge doze inhibitor protonske pumpe sadrži omeprazol, pantoprazol, lansoprazol, ilaprazol, dekslansoprazol, esomeprazol ili rabeprazol, farmaceutski prihvatljive soli ili njihove solvate ili kombinacije navedenog.
6. Kapsula u skladu s patentnim zahtjevom 1, naznačena time što pripravak druge doze sadrži tvar koja odgađa otpuštanje.
7. Kapsula u skladu s patentnim zahtjevom 6, naznačena time što se tvar koja odgađa otpuštanje sastoji od natrijeva alginata, gliceril monostearata, gliceril distearata, akrilnih kiselina, celuloza ili kombinacija navedenog.
8. Kapsula u skladu s patentnim zahtjevom 1, naznačena time što se najmanje 70 % prema težini barem dvaju antibiotika otpušta između 5 i 120 minuta nakon peroralne primjene te se najmanje 70 % prema težini protonskog inhibitora otpušta između 120 i 240 minuta nakon peroralne primjene.
9. Kapsula u skladu s patentnim zahtjevom 1, naznačena time što se sastoji od rifabutina, amoksicilina i omeprazola.
10. Kapsula u skladu s patentnim zahtjevom 9, naznačena time što omjer amoksicilina i rifabutina iznosi između 10 do 40 prema težini.
11. Kapsula u skladu s patentnim zahtjevom 9, naznačena time što omjer amoksicilina i omeprazola iznosi između 20 do 40 prema težini.
12. Kapsula u skladu s patentnim zahtjevom 1, naznačena time što se pripravak prve i druge doze dodatno sastoje od punila, sredstva za raspadanje, veziva, površinski aktivne tvari, alkalizirajućeg sredstva, maziva ili kombinacija navedenog.
13. Kapsula u skladu s patentnim zahtjevom 12, naznačena time što se punilo sastoji od laktoze, celuloze, škroba, kalcijevih fosfata, kalcijeva karbonata, šećera ili kombinacija navedenog.
14. Kapsula u skladu s patentnim zahtjevom 12 ili patentnim zahtjevom 13, naznačena time što se sredstvo za raspadanje sastoji od kroskarmeloza-natrija, karboksimetil-celuloze, natrijeva škrob glikolata, krospovidona ili kombinacija navedenog.
15. Kapsula u skladu s bilo kojim patentnim zahtjevom od 12 do 14, naznačena time što se vezivo sastoji od škroba, celuloze, polivinilpirolidona, ksantan gume, alginske kiseline, agara ili kombinacija navedenog.
16. Kapsula u skladu s bilo kojim patentnim zahtjevom od 12 do 15, naznačena time što se površinski aktivna tvar sastoji od natrijeva lauril-sulfata, polioksietilen polioksipropilen glikola, polietilen glikola, polipropilen glikola, polivinil kaprolaktama--polivinil acetata--polietilen glikola, makrogolglicerol hidroksistearata ili kombinacija navedenog.
17. Kapsula u skladu s bilo kojim patentnim zahtjevom od 12 do 16, naznačena time što se alkalizirajuće sredstvo sastoji od meglumina, kalcijeva karbonata, natrijeva sulfata, natrijeva bikarbonata ili kombinacija navedenog.
18. Kapsula u skladu s bilo kojim patentnim zahtjevom od 12 do 17, naznačena time što se mazivo sastoji od magnezijeva stearata, silicijeva dioksida, talka, stearinske kiseline, natrijeva stearil fumarata, gliceril behenata ili kombinacija navedenog.
19. Kapsula u skladu s patentnim zahtjevom 1, naznačena time što se pripravak prve doze sastoji od 250 mg amoksicilina i 12,5 mg rifabutina ili farmaceutski prihvatljivih soli ili njihovih solvata i što se pripravak druge doze sastoji od 10 mg omeprazola ili farmaceutski prihvatljivih soli ili njihovih solvata.
20. Kapsula u skladu s patentnim zahtjevom 1, naznačena time što se pripravak druge doze sastoji od vanjskog zaštitnog sloja, enterične obloge i unutrašnjeg zaštitnog sloja.
21. Kapsula u skladu s patentnim zahtjevom 1 za primjenu u liječenju infekcije bakterijom H. pylori u domaćinu, naznačena time što se kapsula primjenjuje na domaćinu tri puta dnevno.
22. Kapsula u skladu s patentnim zahtjevom 21, naznačena time što se svakodnevno primjenjuje 3000 mg amoksicilina, 120 mg omeprazola i 150 mg rifabutina.
23. Kapsula u skladu s patentnim zahtjevom 21, naznačena time što se svakodnevno primjenjuje do 4500 mg amoksicilina i do 300 mg rifabutina.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361764401P | 2013-02-13 | 2013-02-13 | |
| US201361764385P | 2013-02-13 | 2013-02-13 | |
| EP14751025.9A EP2956149B1 (en) | 2013-02-13 | 2014-02-12 | Pharmaceutical compositions for the treatment of helicobacter pylori |
| PCT/US2014/016071 WO2014127025A1 (en) | 2013-02-13 | 2014-02-12 | Pharmaceutical compositions for the treatment of helicobacter pylori |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191559T1 true HRP20191559T1 (hr) | 2019-11-29 |
Family
ID=51297592
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191559 HRP20191559T1 (hr) | 2013-02-13 | 2019-08-29 | Farmaceutski pripravci za liječenje infekcije bakterijom helicobacter pylori |
Country Status (26)
| Country | Link |
|---|---|
| US (7) | US9050263B2 (hr) |
| EP (1) | EP2956149B1 (hr) |
| JP (1) | JP6494529B2 (hr) |
| KR (1) | KR102062357B1 (hr) |
| CN (2) | CN105163743A (hr) |
| AU (1) | AU2014216373B2 (hr) |
| BR (1) | BR112015019264B1 (hr) |
| CA (1) | CA2900763C (hr) |
| CL (1) | CL2015002253A1 (hr) |
| CY (1) | CY1122113T1 (hr) |
| DK (1) | DK2956149T3 (hr) |
| ES (1) | ES2744406T3 (hr) |
| HK (1) | HK1217645A1 (hr) |
| HR (1) | HRP20191559T1 (hr) |
| HU (1) | HUE052411T2 (hr) |
| IL (1) | IL240387B (hr) |
| MX (1) | MX368536B (hr) |
| NZ (1) | NZ711754A (hr) |
| PH (1) | PH12015501783B1 (hr) |
| PL (1) | PL2956149T3 (hr) |
| PT (1) | PT2956149T (hr) |
| RU (1) | RU2671400C2 (hr) |
| SG (1) | SG11201506318QA (hr) |
| SI (1) | SI2956149T1 (hr) |
| UA (1) | UA120249C2 (hr) |
| WO (1) | WO2014127025A1 (hr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014127025A1 (en) | 2013-02-13 | 2014-08-21 | Reza Fathi | Pharmaceutical compositions for the treatment of helicobacter pylori |
| KR101884230B1 (ko) * | 2016-02-29 | 2018-08-01 | 주식회사 유영제약 | 에소메프라졸을 포함하는 제제 |
| TW201829003A (zh) * | 2017-01-18 | 2018-08-16 | 台灣基督長老教會馬偕醫療財團法人馬偕紀念醫院 | 胃腸道感染腔內治療系統 |
| EP3551186A4 (en) * | 2017-10-15 | 2020-08-19 | The Center for Digestive Diseases | COMPOSITIONS AND METHODS FOR THE TREATMENT, IMPROVEMENT AND PREVENTION OF H. PYLORI INFECTIONS |
| CN108497546B (zh) * | 2018-03-22 | 2021-03-19 | 宝可科技（上海）有限公司 | 一种烟用添加剂及其制备方法和用途 |
| CN110354125A (zh) * | 2019-08-12 | 2019-10-22 | 珠海赛隆药业股份有限公司 | 一种治疗幽门螺杆菌感染的组合物及其制剂和用途 |
| US11878011B2 (en) | 2020-05-07 | 2024-01-23 | Redhill Biopharma Ltd. | Method for eradicating Helicobacter pylori infection in patients regardless of body mass index |
| WO2023204640A1 (ko) * | 2022-04-22 | 2023-10-26 | 한국생명공학연구원 | 헬리코박터 파일로리에 의한 위 점막 손상 관련 질환의 예방 또는 치료용 약학적 조성물 및 헬리코박터 파일로리 감염의 예방 또는 치료용 유효성분의 스크리닝 플랫폼 |
| CN117398360B (zh) * | 2023-12-14 | 2024-03-15 | 山东齐都药业有限公司 | 治疗幽门螺杆菌的复方制剂胶囊及其制备方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3980637A (en) * | 1975-03-17 | 1976-09-14 | Bristol-Myers Company | Production of amoxicillin |
| SE8301182D0 (sv) * | 1983-03-04 | 1983-03-04 | Haessle Ab | Novel compounds |
| SE9500422D0 (sv) * | 1995-02-06 | 1995-02-06 | Astra Ab | New oral pharmaceutical dosage forms |
| WO1998022117A1 (en) | 1996-11-22 | 1998-05-28 | The Procter & Gamble Company | Compositions for the treatment of gastrointestinal disorders containing bismuth, and nsaid and one or more antimicrobials |
| SE9700885D0 (sv) | 1997-03-12 | 1997-03-12 | Astra Ab | New pharmaceutical formulation |
| SE9704869D0 (sv) * | 1997-12-22 | 1997-12-22 | Astra Ab | New pharmaceutical formulaton II |
| AUPP325398A0 (en) * | 1998-04-30 | 1998-05-21 | Borody, Thomas J. | Improved method for eradicating h. pylori |
| US5927500A (en) * | 1998-06-09 | 1999-07-27 | Milliken & Company | Pharmaceutical containment package |
| JP2000128779A (ja) * | 1998-10-20 | 2000-05-09 | Mitsui Chemicals Inc | 薬物放出制御型製剤 |
| US20040213847A1 (en) * | 2003-04-23 | 2004-10-28 | Matharu Amol Singh | Delayed release pharmaceutical compositions containing proton pump inhibitors |
| WO2005048979A2 (en) * | 2003-10-06 | 2005-06-02 | Torrent Pharmaceuticals Limited | Pharmaceutical composition having casing with multiple micro tablets |
| US7981908B2 (en) * | 2005-05-11 | 2011-07-19 | Vecta, Ltd. | Compositions and methods for inhibiting gastric acid secretion |
| FR2891459B1 (fr) | 2005-09-30 | 2007-12-28 | Flamel Technologies Sa | Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant |
| EP1803450A1 (en) * | 2006-01-03 | 2007-07-04 | Ferrer Internacional, S.A. | Pharmaceutical compositions for the eradication of helicobacter pylori |
| WO2009008005A1 (en) * | 2007-07-06 | 2009-01-15 | Lupin Limited | Pharmaceutical compositions of rifaximin |
| JP5260905B2 (ja) | 2007-07-12 | 2013-08-14 | 株式会社ジャパンディスプレイ | 有機ｅｌ表示装置 |
| JP5032577B2 (ja) | 2007-07-20 | 2012-09-26 | 興和株式会社 | 鉛濃度測定用試薬及び鉛濃度測定方法 |
| CN101888828A (zh) * | 2007-07-27 | 2010-11-17 | 蒂宝制药公司 | 脉冲胃滞留剂型 |
| CN101584681A (zh) * | 2008-05-23 | 2009-11-25 | 黑龙江福和华星制药集团股份有限公司 | 一种用于治疗幽门螺旋杆菌感染的片剂胶囊 |
| CN101607086B (zh) * | 2009-07-21 | 2011-11-02 | 山西安特生物制药股份有限公司 | 一种复方铋剂组合物及其制备方法 |
| CN102091084B (zh) * | 2010-12-09 | 2012-05-09 | 王勇 | 一种复方胶囊及其制备方法 |
| WO2014127025A1 (en) * | 2013-02-13 | 2014-08-21 | Reza Fathi | Pharmaceutical compositions for the treatment of helicobacter pylori |
-
2014
- 2014-02-12 WO PCT/US2014/016071 patent/WO2014127025A1/en active Application Filing
- 2014-02-12 NZ NZ711754A patent/NZ711754A/en not_active IP Right Cessation
- 2014-02-12 CN CN201480016889.0A patent/CN105163743A/zh active Pending
- 2014-02-12 UA UAA201508775A patent/UA120249C2/uk unknown
- 2014-02-12 JP JP2015558108A patent/JP6494529B2/ja active Active
- 2014-02-12 KR KR1020157023788A patent/KR102062357B1/ko active IP Right Grant
- 2014-02-12 CA CA2900763A patent/CA2900763C/en active Active
- 2014-02-12 DK DK14751025.9T patent/DK2956149T3/da active
- 2014-02-12 PL PL14751025T patent/PL2956149T3/pl unknown
- 2014-02-12 SI SI201431336T patent/SI2956149T1/sl unknown
- 2014-02-12 HU HUE14751025A patent/HUE052411T2/hu unknown
- 2014-02-12 BR BR112015019264-5A patent/BR112015019264B1/pt active IP Right Grant
- 2014-02-12 EP EP14751025.9A patent/EP2956149B1/en active Active
- 2014-02-12 US US14/179,197 patent/US9050263B2/en active Active
- 2014-02-12 SG SG11201506318QA patent/SG11201506318QA/en unknown
- 2014-02-12 CN CN201910242271.0A patent/CN109893516A/zh active Pending
- 2014-02-12 AU AU2014216373A patent/AU2014216373B2/en active Active
- 2014-02-12 RU RU2015138708A patent/RU2671400C2/ru active
- 2014-02-12 MX MX2015010490A patent/MX368536B/es active IP Right Grant
- 2014-02-12 PT PT14751025T patent/PT2956149T/pt unknown
- 2014-02-12 ES ES14751025T patent/ES2744406T3/es active Active
- 2014-10-24 US US14/522,921 patent/US9498445B2/en active Active
-
2015
- 2015-08-06 IL IL240387A patent/IL240387B/en active IP Right Grant
- 2015-08-12 CL CL2015002253A patent/CL2015002253A1/es unknown
- 2015-08-13 PH PH12015501783A patent/PH12015501783B1/en unknown
-
2016
- 2016-04-21 US US15/135,309 patent/US9603806B2/en active Active
- 2016-05-16 HK HK16105611.0A patent/HK1217645A1/zh unknown
-
2017
- 2017-03-22 US US15/466,305 patent/US10238606B2/en active Active
-
2019
- 2019-02-13 US US16/274,634 patent/US10898439B2/en active Active
- 2019-07-18 US US16/515,621 patent/US11135172B2/en active Active
- 2019-08-29 HR HRP20191559 patent/HRP20191559T1/hr unknown
- 2019-09-02 CY CY20191100919T patent/CY1122113T1/el unknown
-
2021
- 2021-08-20 US US17/408,111 patent/US11931463B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191559T1 (hr) | Farmaceutski pripravci za liječenje infekcije bakterijom helicobacter pylori | |
| JP2016508516A5 (hr) | ||
| FI122016B (fi) | Protonipumppuinhibiittoria sisältävä farmaseuttinen moniyksikköpreparaatti | |
| KR101908748B1 (ko) | 구강내 붕괴정 | |
| JP2009517466A5 (hr) | ||
| US20090175959A1 (en) | Controlled Release Solid Preparation | |
| JP2012518655A5 (hr) | ||
| JP2011098964A5 (hr) | ||
| JP2005519901A5 (hr) | ||
| TR201816133T4 (tr) | Bi̇r anti̇platelet ajan ve bi̇r asi̇t i̇nhi̇bi̇törü i̇çeren oral dozaj formlari. | |
| ES2435943T3 (es) | Formulaciones de vildagliptina | |
| JP2014533656A5 (hr) | ||
| HRP20120754T1 (hr) | Dozirni oblik koji sadrži pantoprazol kao aktivni sastojak | |
| CN106659690B (zh) | 包括含有活性成分的膜包衣层的复合制剂 | |
| JP2019508464A (ja) | クロピドグレル及びアスピリンを含む複合製剤 | |
| JP2007091648A (ja) | ベンズイミダゾール系プロトンポンプ阻害剤及びｈ２受容体拮抗剤含有医薬組成物 | |
| JP2007091648A6 (ja) | ベンズイミダゾール系プロトンポンプ阻害剤及びｈ２受容体拮抗剤含有医薬組成物 | |
| US20190070159A1 (en) | Novel pharmaceutical uses | |
| CA2648538A1 (en) | Oral rapid release pharmaceutical formulation for pyridylmethylsulfinyl-benzimidazoles | |
| US11052048B2 (en) | Esomeprazole-containing complex capsule and preparation method therefor | |
| AU2005204014B2 (en) | Pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic agent | |
| EP3377046A1 (en) | Pharmaceutical composition containing a non-steroidal antiinflammatory drug and a proton pump inhibitor | |
| CA2740974A1 (en) | Dosage forms for the rapid and sustained elevation of gastric ph | |
| US20120164233A1 (en) | Pulsatile release pharmaceutical formulation of dexlansoprazole | |
| JP2012072061A (ja) | 新規組成物 |